


BME 301

Lecture Fourteen




Prostate Cancer

Early Detection



Statistics on Prostate Cancer


- United States:
 - 218,890 new cases in US
 - 27,050 deaths in US
 - 2nd leading cause of cancer death in men
- Worldwide:
 - Third most common cancer in men
 - 679,000 new cases each year



Risk factors



- Age
 - chance of having prostate cancer rises rapidly after age 50
 - about 2 out of 3 prostate cancers are found in men over the age of 65.
- Race
 - incidence 3x higher in African Americans
 - occurs less often in Asian-American and Hispanic/Latino men than in non-Hispanic whites.
- Family History
 - Having a father or brother with prostate cancer more than doubles a man's risk of developing prostate cancer

Risk of Prostate Cancer in Next 5 Yrs



Development of Prostate Cancer

- Prostate Cancer:
 - Slow, but continuously growing neoplasia
 - Preclinical form develops at age 30
 - Remains latent for up to 20 years
 - Can progress to aggressive, malignant cancer
- Peak incidence: 7th decade of life
- Signs and symptoms:
 - Often asymptomatic in early stages
 - Weak or interrupted urine flow
 - Inability to urinate
 - These are symptoms of prostate enlargement



Prostate Cancer (2005)

- Screening (American Cancer Society recs):
 - Annual serum PSA test beginning at age 50
 - Annual digital rectal exam at age 50
- Treatment:
 - Surgery, radiation therapy, hormone therapy, chemotherapy
- 5 year survival
 - All stages: 98%
 - Localized disease: 100%
 - Distant metastases: 31%

PSA Test

Sandwich
ELISA

The diagram illustrates a sandwich ELISA. A PSA molecule is captured by an antibody immobilized on a solid surface. A second antibody, conjugated with an enzyme, binds to the PSA molecule. The enzyme then catalyzes a reaction to produce a reporter signal.

Normal PSA Levels: < 4 ng/ml
Cancer Patients:
20-25% have PSA < 4 ng/ml
20-25% have 4 ng/ml < PSA < 10 ng/ml
50-60% have PSA > 10 ng/ml


Sensitivity = 63-83%
Specificity = 90%

Digital Rectal Examination

A sagittal cross-section diagram of the male pelvic region, enclosed in a circular frame with a dotted border. The diagram illustrates the internal organs: the Bladder is shown as a large sac-like structure; the Rectum is the terminal part of the large intestine; and the Prostate is the gland situated between the bladder and the rectum. A hand is shown performing a digital rectal examination, with the index finger inserted into the rectum to palpate the prostate gland. Labels with leader lines identify the Bladder, Rectum, and Prostate.

What happens if DRE & PSA are +?

- Biopsy of prostate (\$1500)
 - Insert needle through wall of rectum into prostate
 - Remove fragments of prostate
 - Examine under microscope



Bladder

Seminal vesicle

Prostate

Rectum

Ultrasound probe

Prostate

Rectum

Needle

Biopsy needle

Copyright © 2000, Saunders

<http://tiny.webmd.com/nR/donlres/055>
7C509-9680-4441-AT8E-
12362F6/232CF-1001



Rx for Localized Prostate Cancer

- Radical prostatectomy (remove prostate)
 - Usually curative
 - Serious side effects:
 - Incontinence (2-30%)
 - Impotence (30-90%)
 - Infertility
- Conservative management
 - Just watch until symptoms develop

Does Early Detection Make a Δ ?


- 10 Yr Survival Rates for Localized Prostate CA:
 - Grade I:
 - Surgery 94%
 - Conservative Rx 93%
 - Grade II:
 - Surgery 87%
 - Conservative Rx 77%
 - Grade III:
 - Surgery 67%
 - Conservative Rx 45%
- Makes a difference only for high grade disease

Challenges of Screening

- Prostate cancer is a slow-growing cancer
 - Not symptomatic for an average of 10 years
- Most men with prostate cancer die of other causes
- Treatment has significant side effects
- 50 year old man:
 - 40% chance of developing microscopic prostate cancer
 - 10% chance of having this cancer diagnosed
 - 3% chance of dying of it


Should we screen?

- Yes:
 - Localized prostate cancer is curable
 - Advanced prostate cancer is fatal
 - Some studies (not RCTs) show decreased mortality in screened patients
- No:
 - False-positives lead to unnecessary biopsies
 - Over-detection of latent cancers
 - We will detect many cancers that may never have produced symptoms before patients died of other causes (slow growing cancer of old age)
 - No RCTs showing decreased mortality



Why are RCTs so Important?
Lead Time Bias

Cancer Incidence Rates* for Men, US, 1975-2000
Rate Per 100,000



*Age adjusted to the 2000 US standard population.
Source: Surveillance, Epidemiology, and End Results Program, 1975-2000, Division of Cancer Control and Population Sciences, National Cancer Institute, 2003.

	5-Year Survival, %		% Change (1950-1996)		
	1950-1954	1989-1995	Absolute Increase in 5-Year Survival, %	Mortality	Incidence
Prostate	43%	93%	50%	+10%	+190%
Cervix	59%	71%	12%	-76%	-79%
Ovary	30%	50%	20%	-2%	+3%

Clinical Evidence

- Three case-control studies of DRE
 - Mixed results
- One completed RCT of DRE & PSA
 - Found no difference in # of prostate cancer deaths between groups randomized to screening and usual care

Randomized Clinical Trials Underway

- Prostate Cancer vs. Intervention Trial (US)
- Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (US)
- European Randomized Study for Screening for Prostate Cancer
 - 239,000 men
 - 10 countries
 - Will be complete in 2008

Do All Countries Screen with PSA?

- United States:
 - Conflicting recommendations
- Europe:
 - No
 - Not enough evidence that screening reduces mortality

Conflicting Recommendations in US

- Guide to Clinical Preventive Services
 - Do NOT screen using DRE or serum PSA
- American College of Preventive Medicine
 - Men aged 50 or older with >10 yr life expectancy should be informed and make their own decision
- American Cancer Society (and others)
 - Men aged 50 or older with > 10 yr life expectancy should be screened with DRE and serum PSA

USPSTF Recommendation

- The USPSTF found:
 - good evidence that PSA screening can detect early-stage prostate cancer but mixed and inconclusive evidence that early detection improves health outcomes.
 - Screening is associated with important harms, including frequent false-positive results and unnecessary anxiety, biopsies and potential complications of treatment of some cancers that may never have affected a patient's health.
- The USPSTF concludes:
 - that evidence is insufficient to determine whether the benefits outweigh the harms for a screened population.

American Cancer Society (2008):

- PSA and DRE should be *offered* annually, beginning at age 50, to men who have at least a 10-year life expectancy.
- Information should be provided about what is known and what is uncertain about benefits, limitations, and harms of early detection and treatment of prostate cancer so they can make an informed decision.
- Men who ask their doctor to make the decision on their behalf should be tested. Discouraging testing is not appropriate. Also, not offering testing is not appropriate.

PSA Test

Details

The PSA Test

- What is PSA?
 - Prostate-specific antigen
 - A glycoprotein responsible for liquefaction of semen
 - Highly specific for prostate (only made by the prostate)
- PSA test is a blood test to measure PSA levels
- Why measure PSA to screen for cancer?
 - PSA levels are closely (but not definitively) associated with prostate cancer
 - May be elevated in benign conditions (BPH, Prostatitis)
 - Not always high in cancer
- Cost:
 - \$30-\$100

PSA Levels

- Normal PSA Levels:
 - < 4 ng/ml
 - Can vary by age
 - 40-49 yo < 2.5 ng/ml
 - 50-59 yo < 3.5 ng/ml
 - 60-69 yo < 4.5 ng/ml
 - 70-80 yo < 6.5 ng/ml
- Cancer Patients:
 - 20-25% have PSA < 4 ng/ml
 - 20-25% have 4 ng/ml < PSA < 10 ng/ml
 - 50-60% have PSA > 10 ng/ml

Sensitivity and Specificity of PSA

- How to determine
 - Trial: Serum PSA → Biopsy (Gold standard)
 - If BX is positive and PSA is positive: get TP
 - If BX is positive and PSA is negative: get FN
 - If BX is negative and PSA is negative: get TN
 - If BX is negative and PSA is positive: get FP
 - BUT: if BX is negative:
 - Did BX just fail to sample area with cancer?
 - Hard to calculate Specificity - $TN/(TN+FP)$
- Cutpoint of 4 ng/ml
- Sensitivity = 63-83%
- Specificity = 90%

Predictive Value Calculation

- Screening Performance:
 - Se = 73%; Sp = 90%
- Number Tested:
 - N=1,000,000; Prevalence = 2%
- Costs:
 - Screening = \$30; Follow up biopsy = \$1500
- What are PPV & NPV?
- What is screening cost?
- What is biopsy cost?
- What is cost/cancer found?

PSA Example – Predictive Value

	Test Positive	Test Negative	
Disease Present	14,600	5,400	# with Disease = 20,000
Disease Absent	98,000	882,000	#without Disease = 980,000
	# Test Pos = 112,600	# Test Neg = 887,400	Total Tested = 1,000,000

$$PPV = 14,600 / 112,600 = 13\%$$

$$NPV = 882,000 / 887,400 = 99\%$$


PSA Example – Cost

	Test Positive	Test Negative	
Disease Present	14,600	5,400	# with Disease = 20,000
Disease Absent	98,000	882,000	#without Disease = 980,000
	# Test Pos = 112,600	# Test Neg = 887,400	Total Tested = 1,000,000

$$\text{Cost to Screen} = \$30 \times 1,000,000 + \$1500 \times 112,600 = \$168,900,000$$

$$\text{Cost/Cancer} = \$168,900,000 / 14,600 = \$13,623$$

Health – Policy Space



New Technologies: Improved Screening

- Additional serum markers → Improve Sp
 - Free PSA
 - PSA density
 - PSA velocity
- Predict those cancers which will progress to advanced disease
 - Gene chips

Review of Lecture 14

- Prostate cancer
 - Leading cause of cancer in men in USA
 - 2nd leading cause of cancer death in men in USA
 - Slow growing cancer of old age
 - Precancer→cancer sequence
 - Precancer is very common
- PSA
 - Serum antigen closely (but not exclusively) associated with prostate cancer
- Should we screen with PSA?
 - Early prostate cancer is curable
 - No RCTs showing decreased mortality yet
 - Screening can lead to unnecessary biopsies and over-treatment of latent cancer